ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 mai 2024 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
30 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
29 mai 2024 09h15 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
28 mai 2024 04h00 HE
|
AKAMPION
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
23 mai 2024 17h09 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, May 23, 2024 (GLOBE NEWSWIRE) -- Results will be presented at American Society of Clinical Oncology (ASCO) Annual MeetingMedian overall survival was 20.3 months, nearly doubling the...
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
16 mai 2024 17h29 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
16 mai 2024 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
15 mai 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.